Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Return on Capital Employed (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Return on Capital Employed for 5 consecutive years, with 0.56% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed fell 27.0% to 0.56% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.56%, a 27.0% decrease, with the full-year FY2024 number at 0.45%, down 5.0% from a year prior.
  • Return on Capital Employed was 0.56% for Q3 2025 at 4D Molecular Therapeutics, down from 0.48% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.21% in Q2 2021 to a low of 0.56% in Q3 2025.
  • A 5-year average of 0.34% and a median of 0.34% in 2024 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: rose 21bps in 2024, then decreased -27bps in 2025.
  • 4D Molecular Therapeutics' Return on Capital Employed stood at 0.25% in 2021, then tumbled by -70bps to 0.43% in 2022, then increased by 21bps to 0.34% in 2023, then rose by 0bps to 0.34% in 2024, then plummeted by -65bps to 0.56% in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Return on Capital Employed are 0.56% (Q3 2025), 0.48% (Q2 2025), and 0.4% (Q1 2025).